PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2018 | 8 | 1 | 5-10
Article title

Acute coronary syndromes in oncology: conservative or invasive strategies? Case study and literature review

Content
Title variants
Languages of publication
EN
Abstracts
EN
We present the case of a 70-year-old male patient with metastatic and castration-resistant prostate cancer as well as advanced bladder cancer, who suffered a non-ST-elevation myocardial infarction (NSTEMI). The cause of ischemia was critical left main stem stenosis, and right coronary artery stenosis. Initially, the patient was qualified for conservative treatment, but due to the intensifying symptoms of myocardial ischemia, it was decided that a hemodynamic intervention was necessary. Two drug-eluting stents were implanted, leading to clinical improvement. Following the treatment, the patient was considered as a candidate for further anti-cancer therapy. Unfortunately, due to the bladder cancer progression, anaemia and haemorrhage, his clinical condition exacerbated, and the patient died about 1 month from the cardiac intervention. Apart from the case description, the paper includes a review of literature on the treatment of acute coronary syndromes without ST-segment elevation in cancer patients.
Discipline
Publisher
Journal
Year
Volume
8
Issue
1
Pages
5-10
Physical description
Contributors
author
  • Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Centre, Otwock; Department of Clinical Oncology, European Health Centre, Otwock
  • Department of Clinical Oncology, European Health Centre, Otwock
author
  • Cardiology Centre, Józefów
  • Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Centre, Otwock
  • Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Centre, Otwock
References
  • 1. Moore RA, Adel N, Riedel E et al. High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis. J Clin Oncol 2011; 29: 3466-3473.
  • 2. Roffi M, Patrono C, Collet JP et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37(3): 267-315.
  • 3. Tang EW, Wong CK, Herbison P. Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome. Am Heart J 2007; 153: 29-35.
  • 4. Subherwal S, Bach RG, Chen AY et al. Baseline Risk of Major Bleeding in Non-ST-Segment-Elevation Myocardial Infarction The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score. Circulation 2009; 119(14): 1873-1882.
  • 5. Guddati AK, Joy PS, Kumar G. Analysis of outcomes of percutaneous coronary intervention in metastatic cancer patients with acute coronary syndrome over a 10-year period. J Cancer Res Clin Oncol 2016; 142(2): 471-479.
  • 6. Yusuf SW, Daraban N, Abbasi N et al. Treatment and Outcomes of Acute Coronary Syndrome in the Cancer Population. Clin Cardiol 2012; 35(7): 443-450.
  • 7. Sarkiss MG, Yusuf SW, Warneke CL et al. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer 2007; 109(3): 621-627.
  • 8. Valgimigli M, Bueno H, Byrne RA et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J 2018; 39(3): 213-260.
  • 9. Binder RK, Luscher TF. Duration of dual antiplatelet therapy after coronary artery stenting: where is the sweet spot between ischaemia and bleeding? Eur Heart J 2015; 36(20): 1207-1211.
  • 10. Charakterystyka produktu leczniczego (Zytiga®) [online: https://ec.europa.eu/health/documents/community-register/2016/20161109136263/ anx_136263_pl.pdf].
  • 11. De Bono JS, Logothetis CJ, Molina A et al. Abiraterone and Increased Survival in Metastatic Prostate Cancer. N Engl J Med 2011; 364(21): 1995-2005.
  • 12. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. N Engl J Med 2013; 368(2): 138-148.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-1cd78abc-0025-48fb-82cc-ad88b9d7377d
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.